Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ASP030
MIFTS: 40

Aspirin Resistance

Categories: Blood diseases, Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Aspirin Resistance

About this section

MalaCards integrated aliases for Aspirin Resistance:

Name: Aspirin Resistance 56
Aspirin, Resistance to Cardioprotective Effect of 56
Aspirin, Resistance to Antithrombotic Effect of 56
Aspirin Cardioprotective Effect of 56
Aspirin Antithrombotic Effect of 56

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 56 608223
Sources

Summaries for Aspirin Resistance

About this section
OMIM : 56 Aspirin (acetylsalicylic acid) is a classic nonsteroidal antiinflammatory agent that irreversibly inhibits type I cyclooxygenase (PTGS1, or COX1; 176805) in platelets, resulting in decreased production of thromboxane A2 (TXA2) and inhibition of platelet aggregation. Because of this feature, it is used therapeutically to prevent cardiothrombotic events. Individuals show a variable response to the drug, referred to as aspirin ineffectiveness or resistance, in which not all individuals or populations appear to receive the full prophylactic or therapeutic benefits (summary by Zhou et al., 2011). Halushka and Halushka (2002) discussed a possible basis for resistance to the cardioprotective effect of aspirin. (608223)

MalaCards based summary : Aspirin Resistance, also known as aspirin, resistance to cardioprotective effect of, is related to active peptic ulcer disease and cerebrovascular disease. An important gene associated with Aspirin Resistance is PTGS1 (Prostaglandin-Endoperoxide Synthase 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Development Angiotensin activation of ERK. The drugs Cilostazol and Dipyridamole have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and kidney, and related phenotypes are homeostasis/metabolism and muscle

Sources

Related Diseases for Aspirin Resistance

About this section

Diseases related to Aspirin Resistance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 active peptic ulcer disease 29.7 PTGS2 PTGS1
2 cerebrovascular disease 29.6 ITGB3 ITGA2 APOB
3 clopidogrel resistance 29.3 PTGS2 P2RY1 ITGB3
4 thrombosis 29.2 P2RY1 ITGB3 ITGA2
5 vascular disease 28.5 PTGS2 PTGS1 ITGB3 ITGA2 APOB
6 myocardial infarction 28.0 PTGS2 PTGS1 ITGB3 ITGA2 APOB
7 arteries, anomalies of 10.5
8 hyperlipoproteinemia, type iii 10.5
9 coronary artery anomaly 10.5
10 stroke, ischemic 10.4
11 ischemia 10.4
12 intermediate coronary syndrome 10.3
13 peripheral vascular disease 10.2
14 heart disease 10.2
15 hypercholesterolemia, familial, 1 10.1
16 coronary heart disease 1 10.1
17 gas gangrene 10.1
18 diabetes mellitus 10.1
19 body mass index quantitative trait locus 1 10.1
20 kidney papillary necrosis 10.1 PTGS2 PTGS1
21 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1 PTGS2 PTGS1
22 peptic ulcer disease 10.0 PTGS2 PTGS1
23 chronic cystitis 10.0 PTGS2 PTGS1
24 hydrops, lactic acidosis, and sideroblastic anemia 10.0 PTGS2 PTGS1
25 pre-eclampsia 10.0
26 transient cerebral ischemia 10.0
27 lipid metabolism disorder 10.0
28 chronic acquired demyelinating polyneuropathy 10.0
29 antenatal bartter syndrome 10.0 PTGS2 PTGS1
30 morphine dependence 10.0 PTGS2 PTGS1
31 atherosclerosis susceptibility 10.0
32 angina pectoris 10.0
33 diabetic angiopathy 10.0
34 carotid stenosis 10.0
35 intermittent claudication 10.0
36 kidney disease 10.0
37 coronary thrombosis 10.0 PTGS2 ITGB3
38 viral encephalitis 10.0 PTGS2 PTGS1
39 placental abruption 9.9 PTGS2 PTGS1
40 gastric ulcer 9.9 PTGS2 PTGS1
41 body mass index quantitative trait locus 11 9.9
42 body mass index quantitative trait locus 9 9.9
43 homocysteinemia 9.9
44 body mass index quantitative trait locus 8 9.9
45 body mass index quantitative trait locus 4 9.9
46 body mass index quantitative trait locus 10 9.9
47 body mass index quantitative trait locus 7 9.9
48 body mass index quantitative trait locus 12 9.9
49 body mass index quantitative trait locus 14 9.9
50 body mass index quantitative trait locus 18 9.9

Graphical network of the top 20 diseases related to Aspirin Resistance:



Diseases related to Aspirin Resistance
Sources

Symptoms & Phenotypes for Aspirin Resistance

About this section

Clinical features from OMIM:

608223

MGI Mouse Phenotypes related to Aspirin Resistance:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.43 APOB ITGA2 ITGB3 P2RY1 PTGS1 PTGS2
2 muscle MP:0005369 8.92 APOB ITGB3 PTGS1 PTGS2
Sources

Drugs & Therapeutics for Aspirin Resistance

About this section

Drugs for Aspirin Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Dipyridamole Approved Phase 4 58-32-2 3108
3
Tirofiban Approved Phase 4 144494-65-5 60947
4
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
5
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
6
Triflusal Approved, Investigational Phase 4 322-79-2
7
Thrombin Approved, Investigational Phase 4
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Pravastatin Approved Phase 4 81093-37-0 54687
10
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
11
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
12 Acetylsalicylic acid lysinate Phase 4
13 lysine Phase 4
14 Respiratory System Agents Phase 4
15 Anti-Asthmatic Agents Phase 4
16 Protective Agents Phase 4
17 Neuroprotective Agents Phase 4
18 Vasodilator Agents Phase 4
19 Bronchodilator Agents Phase 4
20 Autonomic Agents Phase 4
21 Phosphodiesterase 3 Inhibitors Phase 4
22 Phosphodiesterase Inhibitors Phase 4
23 Aspirin, Dipyridamole Drug Combination Phase 4
24 Anti-Bacterial Agents Phase 4
25 polysaccharide-K Phase 4
26 Immunologic Factors Phase 4
27 Anti-Infective Agents Phase 4
28 Antibiotics, Antitubercular Phase 4
29 Radiation-Protective Agents Phase 4
30 Adjuvants, Immunologic Phase 4
31 Interferon Inducers Phase 4
32 interferons Phase 4
33 calcium heparin Phase 4
34 Antiviral Agents Phase 4
35 Hemostatics Phase 4
36 Coagulants Phase 4
37 Salicylates Phase 4
38 Hypolipidemic Agents Phase 4
39 Anticholesteremic Agents Phase 4
40 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
41 Antimetabolites Phase 4
42 Lipid Regulating Agents Phase 4
43 Chinese Salvia Phase 4
44 Calcium, Dietary Phase 4
45 Hormones Phase 4
46
Esomeprazole Approved, Investigational Phase 3 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
47 Anti-Ulcer Agents Phase 3
48 Gastrointestinal Agents Phase 3
49 Antacids Phase 3
50 Proton Pump Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients Unknown status NCT01935193 Phase 4 lysine acetylsalicylate
2 a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
3 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
4 Validation of the Clinical Applicability of Various Platelet Function Assessments in High-Risk Atherothrombotic Patients Undergoing Percutaneous Coronary Angioplasty: Phase 4 Study Unknown status NCT00513149 Phase 4 Clopidogrel
5 Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients Completed NCT00446641 Phase 4 Cilostazol;placebo
6 A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
7 Aspirin Responsiveness in Women at Risk for Cardiac Events: A Pilot Study. Completed NCT00818337 Phase 4 Aspirin
8 Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting Completed NCT01159639 Phase 4 Clopidogrel
9 Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. Completed NCT00222261 Phase 4 aspirin;clopidogrel
10 Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Completed NCT00398463 Phase 4 Tirofiban;Placebo
11 Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin Completed NCT00262561 Phase 4 Aspirin
12 Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events Completed NCT02616497 Phase 4 Aspirin;Triflusal
13 Aspirin Statins Or Both For The Reduction Of Thrombin Generation In Diabetic People Completed NCT00793754 Phase 4 Aspirin;Atorvastatin;Aspirin + Atorvastatin
14 Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index With Stable Angina Pectoris of Coronary Heart Disease as an Example Completed NCT01502943 Phase 4 Louxiangdan Tongxin granules;TCM granules placebo;Chixiangshen Tongxin granules;TCM granule placebo plus western basis treatment;Western basis treatment
15 The Effect of 81mg vs 162mg ASA for Preeclampsia Prevention in Obese Women at High Risk for Developing Preeclampsia Recruiting NCT03735433 Phase 4 162mg aspirin dose
16 Efficacy of Monitoring of Aspirin Responsiveness in the Prevention of Cardiovascular Events and Decrease in Bleeding Complications in Patients With End-Stage Kidney Disease Undergoing Hemodialysis Withdrawn NCT01198379 Phase 4 aspirin;Placebo
17 Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents Withdrawn NCT00589862 Phase 4 Plavix (Clopidogrel)
18 Methods to Augment the Efficacy of Aspirin and Clopidogrel in Healthy Subjects (ASA Only) and Patients With Stable Coronary Artery Disease (Taking Clopidogrel Only) or (Taking Clopidogrel & ASA) With an Elevated Platelet Turnover (Reticulated Platelets). Withdrawn NCT01011257 Phase 4 Asprin;Clopidogrel
19 ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery(TEG-CABG Trial):Does Intensified Postoperative Antiplatelet Therapy in Preoperatively Identified Hypercoagulable Patients Improve Outcome After CABG Surgery Unknown status NCT01046942 Phase 3 Clopidogrel+acetylsalicylic acid;acetylsalicylic acid
20 Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance in The Patients Treated With Primary PCI for STEMI Unknown status NCT00697021 Phase 3 Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG;Aspirin 100mg and Plavix 75mg
21 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
22 Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery Completed NCT00330772 Phase 3 Aspirin;Clopidogrel
23 The Effects of Omega-3 Fatty Acids on Aspirin Resistance Completed NCT00771914 Phase 1, Phase 2 Aspirin;Lovaza;Both Aspirin and Lovaza
24 Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery Completed NCT01618006 Phase 2 Aspirin;Aspirin;Aspirin
25 Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B Completed NCT01902498 Phase 2 Aspirin;Aspirin;Aspirin
26 The Effects of Fish Oil and Aspirin on Cardiovascular Risk in Type 2 Diabetes Completed NCT01181882 Phase 2
27 ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial Terminated NCT02326350 Phase 2 Aspirin 75mg;Lactose powder
28 Bleeding Volume Test: A Double-Blind Crossover Randomized Clinical Trial of an In-Vivo On-Line Test for Aspirin Effect and Resistance Unknown status NCT01047722 Phase 1 Aspirin ingestion followed by doing a Bleeding Volume Test
29 Mechanism Based Resistance to Aspirin Completed NCT00948987 Phase 1 Aspirin
30 Vascular Damage in Systemic Lupus Erythematosus (SLE) Completed NCT00731302 Phase 1 aspirin and meloxicam
31 Phase 1 Study to Assess the Safety of 500mg of Aspirin Added to IV TPA at Standard Doses to Prevent Re-occlusion of Cerebral Vessels After Successful Reperfusion. Withdrawn NCT00417898 Phase 1 Aspirin
32 Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient Unknown status NCT01045785
33 Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary PCI and CABG Population Unknown status NCT01408927
34 Is There A LIfe for DES After Discontinuation of Clopidogrel:The ITALIC PLUS Trial Unknown status NCT01476020
35 Thrombin Dysregulation Leads to Early Saphenous Vein Graft Failure Unknown status NCT00481806
36 Effects of Prescription OMega-3 Fatty Acids (Omacor®, Lovaza®) on Platelet Activity in Patients With Coronary Artery Disease With Hypertriglyceridemia (OMPA-CAD) Unknown status NCT01086163 Omacor, omega-3 fatty acids in CAD patients
37 Prevalence of Aspirin Resistance in Hemodialysis Patients Completed NCT00792272
38 Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients Completed NCT01364779
39 Cardiovascular Events at One Year of Patients Hospitalized for Critical Limb Ischaemia and Aspirin Resistant Using the VerifyNow®. Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia Completed NCT01104441
40 Genotypic and Phenotypic Correlates of Resistance to Anti-platelet Actions of Aspirin in an At-risk Patient Population and in the General Population Completed NCT01361620 aspirin
41 Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients Completed NCT00649909
42 Aspirin Responsiveness in Women With Coronary Artery Disease Completed NCT01406990
43 Comparative Evaluation of Aspirin Resistance With Point-of-Care Testing - Danish Aspirin Resistance Trial (DANART) - Pilot Study Completed NCT00389129 acetylsalicylic acid
44 Evaluation of Aspirin Resistance at a Molecular Level in Aspirin-Treated Patients With Coronary Artery Disease Completed NCT00753935 Early Phase 1 enteric-coated aspirin;Chewable aspirin
45 Laboratory Aspirin Resistance in Coronary Artery Disease Patients With or Without Diabetes Mellitus Completed NCT00563875 acetylsalicylic acid
46 Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel Completed NCT00262275 Aspirin, Clopidogrel
47 The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study)－A Prospective Multicenter Cohort Study- Completed NCT00250380
48 The Effect of Serum LDL Lowering on Aspirin Resistance Completed NCT00466154 Aspirin
49 Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial) Completed NCT03930875
50 Efficacité du Traitement antiagrégant Par Acide acétylsalicylique en Chirurgie Vasculaire mesurée Par agrégométrie Par impédance Completed NCT01432652

Search NIH Clinical Center for Aspirin Resistance

Sources

Genetic Tests for Aspirin Resistance

About this section
Sources

Anatomical Context for Aspirin Resistance

About this section

MalaCards organs/tissues related to Aspirin Resistance:

40
Testes, Heart, Kidney, Whole Blood, Endothelial, Monocytes
Sources

Publications for Aspirin Resistance

About this section

Articles related to Aspirin Resistance:

(show top 50) (show all 718)
# Title Authors PMID Year
1
Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. 56 61
21844189 2011
2
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. 61 56
11940542 2002
3
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. 56 61
11472699 2001
4
Development of aspirin resistance in persons with previous ischemic stroke. 61 56
7974569 1994
5
Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? 56
11940535 2002
6
One hundred years of aspirin. 56
9259670 1997
7
Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. 56
8312766 1994
8
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. 56
8298418 1994
9
Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. 56
8054013 1994
10
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. 56
1907252 1991
11
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. 56
5284360 1971
12
Aspirin selectively inhibits prostaglandin production in human platelets. 56
5284361 1971
13
Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. 56
13013156 1953
14
Aspirin Resistance Incidence and Associations Between Aspirin Effect and Outcomes in Cardiac Surgery. 61
31238032 2019
15
Effects of aspirin resistance and mean platelet volume on vascular access failure in hemodialysis patients. 61
30025441 2019
16
Determinants of aspirin resistance in patients with type 2 diabetes. 61
31783142 2019
17
Aspirin resistance mediated by oxidative stress-induced 8-Isoprostaglandin F2. 61
30989683 2019
18
Aspirin Resistance Significantly Influences Clinical and Economic Burden In Cardiac Surgery Patients. 61
31586618 2019
19
Aspirin Resistance Significantly Influences Clinical and Economic Burden In Cardiac Surgery Patients (Reply). 61
31593655 2019
20
Correlation of Cardiovascular Risk Factors and Biomarkers With Platelet Reactivity in Coronary Artery Disease. 61
30418226 2019
21
Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis. 61
31511539 2019
22
The dilemma of aspirin resistance in obese patients. 61
31660303 2019
23
Aspirin Resistance: Cardiovascular Risk Game Changer. 61
29757761 2019
24
The potential of acetylsalicylic acid and vitamin E in modulating inflammatory cascades in chickens under lipopolysaccharide-induced inflammation. 61
31533824 2019
25
Modulation of microRNAs by aspirin in cardiovascular disease. 61
31444100 2019
26
Metabolic Syndrome and the Effectiveness of Low-dose Aspirin on Reproductive Outcomes. 61
30985534 2019
27
[Network pharmacology-based study on mechanisms of Danhong Injection in treatment of aspirin resistance]. 61
31359682 2019
28
Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke. 61
30795966 2019
29
Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study. 61
31007424 2019
30
Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism. 61
31356179 2019
31
Obesity and laboratory aspirin resistance in high-risk pregnant women treated with low-dose aspirin. 61
30786253 2019
32
Investigation into the causes of aspirin resistance in healthy dogs. 61
30302763 2019
33
Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort. 61
30586555 2019
34
Assessment of the relationship between platelet reactivity, vascular risk factors and gender in cerebral ischaemia patients. 61
31343071 2019
35
Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. 61
30820515 2019
36
Prevalence of aspirin resistance by thromboelastography plus platelet mapping in children with CHD: a single-centre experience. 61
30501653 2019
37
Complex roles of the old drug aspirin in cancer chemoprevention and therapy. 61
29855050 2019
38
Metabolomic Analysis of Platelets of Patients With Aspirin Non-Response. 61
31680941 2019
39
Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients. 61
30098132 2019
40
Diabetes and Platelet Response to Low-Dose Aspirin. 61
30265320 2018
41
Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. 61
29090588 2018
42
Multifaceted effects of arachidonic acid and interaction with cyclic nucleotides in human platelets. 61
30240944 2018
43
The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study. 61
29888621 2018
44
Aspirin resistance in the early postoperative period: Pharmacokinetics may be part of the answer. 61
30538026 2018
45
Aspirin in primary prevention for patients with diabetes: Still a matter of debate. 61
30011059 2018
46
Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients. 61
30016728 2018
47
Evidence and prospective of plant derived flavonoids as antiplatelet agents: Strong candidates to be drugs of future. 61
29448091 2018
48
Potential of Anthocyanin to Prevent Cardiovascular Disease in Diabetes. 61
29477135 2018
49
Association of GPIa and COX-2 gene polymorphism with aspirin resistance. 61
28948649 2018
50
PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study. 61
29055181 2018
Sources

Variations for Aspirin Resistance

About this section
Sources

Expression for Aspirin Resistance

About this section
Search GEO for disease gene expression data for Aspirin Resistance.
Sources

Pathways for Aspirin Resistance

About this section

Pathways related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 12.91 P2RY1 ITGB3 ITGA2 APOB
2
Development Angiotensin activation of ERK 22
Show member pathways
 12.46 P2RY1 ITGB3 ITGA2
3
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.02 PTGS2 PTGS1 ITGB3
4
Folate Metabolism 1
Show member pathways
 11.83 PTGS2 PTGS1 APOB
5
Small cell lung cancer 36
11.56 PTGS2 ITGA2
6
Angiogenesis (CST) 4
11.54 PTGS2 ITGB3
7
Phagocytosis of Microbes 63
11.51 ITGB3 ITGA2
8
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.43 PTGS2 ITGB3
9
Platelet activation 36
11.35 PTGS1 P2RY1 ITGB3 ITGA2
10
Celecoxib Pathway, Pharmacodynamics 60
11.33 PTGS2 PTGS1
11
ECM proteoglycans 65
11.31 ITGB3 ITGA2
12
Regulation of lipolysis in adipocytes 36
11.29 PTGS2 PTGS1
13
Cell adhesion_Endothelial cell contacts by non-junctional mechanisms 22
11.11 ITGB3 ITGA2
14
Prostaglandin Synthesis and Regulation 1
10.97 PTGS2 PTGS1
15
Ibuprofen Pathway, Pharmacodynamics 60
10.92 PTGS2 PTGS1
16
HETE and HPETE biosynthesis and metabolism 22
Show member pathways
 10.86 PTGS2 PTGS1
17
Eicosanoid Synthesis 1
10.78 PTGS2 PTGS1
18
Prostaglandin 2 biosynthesis and metabolism FM 22
10.73 PTGS2 PTGS1
19
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
10.63 PTGS1 P2RY1 ITGB3 ITGA2
20
Overview of nanoparticle effects 1
10.54 PTGS2 PTGS1
21
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 60
10.33 PTGS2 PTGS1
Sources

GO Terms for Aspirin Resistance

About this section

Cellular components related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin complex GO:0008305 8.62 ITGB3 ITGA2

Biological processes related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cell-matrix adhesion GO:0007160 9.59 ITGB3 ITGA2
2 response to organic substance GO:0010033 9.58 PTGS2 APOB
3 viral entry into host cell GO:0046718 9.58 ITGB3 ITGA2
4 blood coagulation GO:0007596 9.58 P2RY1 ITGB3 ITGA2
5 cellular oxidant detoxification GO:0098869 9.57 PTGS2 PTGS1
6 cellular response to mechanical stimulus GO:0071260 9.56 PTGS2 ITGA2
7 fatty acid biosynthetic process GO:0006633 9.55 PTGS2 PTGS1
8 cellular response to organic cyclic compound GO:0071407 9.54 P2RY1 ITGA2
9 regulation of blood pressure GO:0008217 9.52 PTGS2 PTGS1
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.51 PTGS2 ITGA2
11 sensory perception of pain GO:0019233 9.49 PTGS2 P2RY1
12 prostaglandin metabolic process GO:0006693 9.48 PTGS2 PTGS1
13 cell adhesion mediated by integrin GO:0033627 9.46 ITGB3 ITGA2
14 positive regulation of smooth muscle contraction GO:0045987 9.43 PTGS2 ITGA2
15 cellular response to ATP GO:0071318 9.37 PTGS2 P2RY1
16 cell-substrate adhesion GO:0031589 9.32 ITGB3 ITGA2
17 prostaglandin biosynthetic process GO:0001516 9.26 PTGS2 PTGS1
18 mesodermal cell differentiation GO:0048333 9.16 ITGB3 ITGA2
19 cyclooxygenase pathway GO:0019371 8.96 PTGS2 PTGS1
20 wound healing GO:0042060 8.8 P2RY1 ITGB3 ITGA2

Molecular functions related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dioxygenase activity GO:0051213 9.26 PTGS2 PTGS1
2 virus receptor activity GO:0001618 9.16 ITGB3 ITGA2
3 peroxidase activity GO:0004601 8.96 PTGS2 PTGS1
4 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS2 PTGS1
Sources

Sources for Aspirin Resistance

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....